ArticleBriefings in bioinformatics2026
TriDTI: tri-modal representation learning with cross-modal alignment for drug-target interaction prediction.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CMA-DTI: a cross-modal fusion and attentive interaction network for interpretable drug-target interaction prediction.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The rapid advancement of artificial intelligence has positioned drug-target interaction (DTI) prediction as a promising approach in drug screening and drug discovery. Recent research has attempted to use pharmacological multimodal information to increase prediction accuracy. However, existing approaches are limited in fully utilizing more than three modalities, primarily due to information loss during the modality integration process. To overcome this challenge, we propose TriDTI, a novel framework that incorporates three modalities for both drugs and proteins. Specifically, TriDTI integrates structural, sequential, and relational modalities from both entities. To mitigate information loss during integration, we employ projection and cross-modal contrastive learning for modality alignment. Furthermore, we design a fusion strategy that combines soft attention and cross-attention to effectively integrate multimodal representations. Extensive experiments on three benchmark datasets demonstrate that TriDTI consistently achieves superior performance to existing state-of-the-art approaches in DTI prediction. Moreover, TriDTI exhibits a robust generalization ability across three challenging cold-start scenarios, effectively predicting interactions involving novel drugs, targets, and bindings. These results highlight the potential of TriDTI as a robust and practical framework for facilitating drug discovery. The source codes and datasets are publicly accessible at https://github.com/knhc1234/TriDTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.